Drug Profile
Research programme: respiratory and inflammatory disease therapeutics - Argenta/AstraZeneca/BioFocus
Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Argenta; AstraZeneca; BioFocus DPI
- Developer Argenta; BioFocus DPI
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation; Respiratory tract disorders
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Respiratory tract disorders in Netherlands (PO)
- 23 Feb 2023 Discontinued - Preclinical for Respiratory tract disorders in United Kingdom (PO)
- 23 Feb 2023 Discontinued for Inflammation in United Kingdom (unspecified route)